Top

Published in:

01-12-2016 | Commentary

What is the truth about renin angiotensin blockers for diabetic patients?

Author: Atsuko Abiko

Published in: Diabetology International | Issue 4/2016

Excerpt

Many type 2 diabetic patients have concomitant hypertension. These patients require treatment to maintain their blood pressure (BP) within acceptable ranges to decrease the risk of cardiovascular disease or diabetic nephropathy. Lowering BP can decrease the risk or slow the progression of diabetic nephropathy, and thus it is important to evaluate diabetic patients with albuminuria and perform proper staging of diabetic nephropathy. In the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study in 2009 [1], of 11,140 patients with type 2 diabetes, those who achieved lower BP presented fewer renal events. …

de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, Neal B, Poulter N, Harrap S, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Glasziou P, Grobbee DE, MacMahon S, Chalmers J, ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20:883–92.CrossRefPubMedPubMedCentral

The Japanese Diabetes Society. Guideline for the Treatment for Diabetes in Japan 2016. Nankodo Co., Ltd., Tokyo; 2016 (Japanese).

The Japanese Society of Hypertension. Guideline for the management of hypertension 2014. Life Science Publishing Co., Ltd., Tokyo; 2014 (Japanese).

American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2016;39(Suppl. 1):S60–71.

ACCORD Study Group. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood–pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1575–85.

Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm M, Williams B, Yusoff K, Teo K. Yusuf S; ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74–83.CrossRefPubMed

Edmin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes A systematic review and meta-analysis. JAMA. 2015;313:603–15.CrossRef

Bangalore S, fakheri R, Toklu B, messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systemic review and meta-analysis of randomizes trials. BMJ. 2016; 352:i438. doi:10.1136/bmj.i438.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72.CrossRefPubMed

10.

Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U, ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med. 2005;165:1401–9.CrossRefPubMed

11.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.CrossRefPubMed

12.

Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheeler DC, Strippoli GF. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047–56.CrossRefPubMed

13.

Wu H-Y, Huang J-W, Lin H-J, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ. 2013;347:f6008.CrossRefPubMedPubMedCentral

14.

Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64:821–35.CrossRefPubMed

15.

Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the US continues to decline. Diabetes Care. 2010;33:73–7.CrossRefPubMedPubMedCentral

16.

Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec. 31, 2014 (Japanese). http://docs.jsdt.or.jp/overview/index.html.

Title: What is the truth about renin angiotensin blockers for diabetic patients?
Author: Atsuko Abiko
Publication date: 01-12-2016
Publisher: Springer Japan
Published in: Diabetology International / Issue 4/2016
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI: https://doi.org/10.1007/s13340-016-0285-8

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

What is the truth about renin angiotensin blockers for diabetic patients?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2016

M2 macrophages in metabolism

Clinical backgrounds associated with discrepancy between subjective and objective assessments of medication adherence in Japanese type 2 diabetic patients

Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study

Influence of different methods for measuring HbA1c on health checkups in a rural town in Hokkaido, Japan

Smoking status is associated with mild cognitive impairment assessed with the mini-mental state examination in Japanese diabetic patients

A comparison of IDeg + IAsp versus IDet + IAsp in subjects with type 1 diabetes: subgroup analysis of Japanese subjects

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page